Oxymorphone: A review

Eric Prommer

doi:10.1007/s00520-005-0917-1

Oxymorphone: A review

Eric Prommer

Hematology/Oncology

Research output: Contribution to journal › Review article › peer-review

57 Scopus citations

Abstract

Oxymorphone (oxymorphone hydrochloride) (14-hydroxydihydromorphinone), a semisynthetic μ-opioid agonist, was first approved by the US Food and Drug Administration in 1959. Oxymorphone is considered a more potent opioid than its parent compound, morphine. Recently, an immediate-release and long-acting oral formulation of this drug was developed that makes oxymorphone a new option in treating moderate to severe pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this new option in treating moderate to severe pain.

Original language	English (US)
Pages (from-to)	109-115
Number of pages	7
Journal	Supportive Care in Cancer
Volume	14
Issue number	2
DOIs	https://doi.org/10.1007/s00520-005-0917-1
State	Published - Feb 2006

Keywords

Opioid
Opioid receptors
Oxymorphone
Pharmacokinetics

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s00520-005-0917-1

Cite this

@article{0222d5b47c204127b894cf4c63be6ea7,

title = "Oxymorphone: A review",

abstract = "Oxymorphone (oxymorphone hydrochloride) (14-hydroxydihydromorphinone), a semisynthetic μ-opioid agonist, was first approved by the US Food and Drug Administration in 1959. Oxymorphone is considered a more potent opioid than its parent compound, morphine. Recently, an immediate-release and long-acting oral formulation of this drug was developed that makes oxymorphone a new option in treating moderate to severe pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this new option in treating moderate to severe pain.",

keywords = "Opioid, Opioid receptors, Oxymorphone, Pharmacokinetics",

author = "Eric Prommer",

year = "2006",

month = feb,

doi = "10.1007/s00520-005-0917-1",

language = "English (US)",

volume = "14",

pages = "109--115",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Oxymorphone

T2 - A review

AU - Prommer, Eric

PY - 2006/2

Y1 - 2006/2

N2 - Oxymorphone (oxymorphone hydrochloride) (14-hydroxydihydromorphinone), a semisynthetic μ-opioid agonist, was first approved by the US Food and Drug Administration in 1959. Oxymorphone is considered a more potent opioid than its parent compound, morphine. Recently, an immediate-release and long-acting oral formulation of this drug was developed that makes oxymorphone a new option in treating moderate to severe pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this new option in treating moderate to severe pain.

AB - Oxymorphone (oxymorphone hydrochloride) (14-hydroxydihydromorphinone), a semisynthetic μ-opioid agonist, was first approved by the US Food and Drug Administration in 1959. Oxymorphone is considered a more potent opioid than its parent compound, morphine. Recently, an immediate-release and long-acting oral formulation of this drug was developed that makes oxymorphone a new option in treating moderate to severe pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this new option in treating moderate to severe pain.

KW - Opioid

KW - Opioid receptors

KW - Oxymorphone

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=31044432216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31044432216&partnerID=8YFLogxK

U2 - 10.1007/s00520-005-0917-1

DO - 10.1007/s00520-005-0917-1

M3 - Review article

C2 - 16317569

AN - SCOPUS:31044432216

SN - 0941-4355

VL - 14

SP - 109

EP - 115

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 2

ER -

Oxymorphone: A review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this